New Jersey Opiate Addiction Treatment – ParkBenchGroup.com New Jersey Opiate Addiction Treatment from Park Bench Group is a progressive addiction rehabilitation facility offering the most current successful therapeutic treatments available. We provide individual therapy as well as a variety of intensive group experiences conducted by certified therapists who truly care about their clients ( See Testimonials ). Our programs offer a unique insight into each participant’s disease process resulting in a high success rate. A personalized treatment plan and recovery program in a beautiful by the beach in New Jersey setting is designed specifically for each client and makes our individual therapies extremely effective. The Park Bench story is one of transition from illness to recovery from codependency and enabling to tough love and the saving of ourselves – from a place of despair to a place of reflection… from merely existing to truly living a fulfilling life. Park Bench’s inpatient services Park Bench’s inpatient services include beachfront sober housing along the eastern shore of Atlantic City. Clients reside in a complimentary mansion supervised by skilled Park Bench employees. Our “boutique” program affords our clients comfort and serenity as they enjoy all that the seashore has to offer, while recovering in an intensive therapy environment. Therapy at Park Bench exceeds all expectations and state requirements with group therapy, individual therapy, psychiatric evaluation and treatment, discharge planning and …

Rutgers program looks to help women battle alcohol dependency

Filed under: drug treatment programs nj

Piscataway, NJ – (L to R) Program manager Ayorkor Gaba and research professor Elizabeth Epstein of the Women's Treatment Project at the Center of Alcohol Studies, Tuesday, February 19, 2013, at Rutgers University. … Women who inquire about the …
Read more on MyCentralJersey.com

Soligenix Reports Year-End 2012 Financial Results and Highlights Recent …

Filed under: drug treatment programs nj

Schaber continued, "In January, we were pleased to receive an invitation from the Biomedical Advanced Research and Development Authority (BARDA) to submit a contract proposal for the development of OrbeShield™ for the treatment of gastrointestinal …
Read more on PharmaLive (press release) (subscription)